Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Malignant Melanoma (US)

Analysis of: VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival (www.pipelinereview.com)
While the results are impressive for velcade/dex vs. VAD, most would not consider VAD a standard induction regimen.   Likely to be good news in the long run for Millenium, but many will want to see comparison data for velcade and thalidomide in the induction setting    ...
Analysis of: Health Technology Assessment Validates Extracranial Radiosurgery Treatments Particularly Those Delivered With CyberKnife(R) (www.medicalnewstoday.com)
This state of the art robotic LINAC allows for intracranial and extracranial stereotactic radiosurgery, and has exploded on the scene with excellent treatment results        
Analysis of: The Newest in Fluoroscopy Technology (www.dentalcompare.com)
Varian's flat panel is not digital fluoroscopy for treatment planning, but for image guided radiotherapy for daily treatment delivery - a big difference.   This panel is for a state of the art treatment delivery techniquie    
June 29, 2007
Not so quick
Analysis of: Panel Endorses New Anti-Tumor Treatment (www.therapeuticsdaily.com)
How can the FDA approve something that fails to meet the primary endpoint of the trial?   Hence the approval letter            
Analysis of: Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer (www.pipelinereview.com)
While phase I and phase II data can show promising results, the proof in concept is whether a novel agent improves over standard of care medicine.   This is another example of a 'promising' drug that has not proven itself. 
Analysis of: New Cancer Drugs Prove Their Worth (www.dentalplans.com)
These drugs already have a proven value.
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
June 18, 2007
Dermlex Launch
Analysis of: Advitech to finally launch Dermylex in US (www.nutraingredients-usa.com)
Advitech's launch of Dermylex will not have much of an impact on the psoriasis market. This is due to the fact that the product has minimal studies to back it up, and the company will rely on testimonials. This is not an effective way of marketing to physicians, and is difficult with patients....
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
Analysis of: Diets High in Meat Linked With Greater Skin Cancer Risk (www.medscape.com)
This is an interesting study, and one that is difficult to perform and get good data. My biggest concern is whether or not the presumed association between diet and skin cancer is actually due to other factors that could also be present in these patients. For example, what if people in this area who...
June 5, 2007
Melafind
Analysis of: Digital Diagnosis: New Tool for Detecting Skin Cancer (www.ehponline.org)
Depending on the accuracy and cost of the technology, this device could be a useful and welcome tool in melanoma diagnosis.  To be considered useful, the Melafind device must increase melanoma recognition without a significant false negative rate.  In other words, the machines ability to catch...
Eric Whitman, MD, Medical Director, Office of Grants and Research
Eric Whitman, MD, Medical Director, Office of Grants and Research
Atlantic Health System Inc
Analysis of: Neoprobe Announces Interim Phase 2 Lymphoseek Results (www.pipelinereview.com)
Melanoma and breast cancer were chosen because they are the two cancers that most often have sentinel node biopsy done as part of their treatment. Intraoperative lymphatic mapping, or sentinel node biopsy (interchangeable tems for all practical purposes) identifies lymph node metastases at their earliest,...

Previous Page : 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next121 to 130 of 159

Analytics


Generated at 2009-01-07T19:00:58.307